Sanofi has announced the launch of its inactivated rabies vaccine, Verorab, in the UK for all age groups with pre-exposure and post-exposure prophylaxis for rabies. Licensed in the UK since November ...
Das Unternehmen Sanofi stellt in Deutschland von Tollwut-Impfstoff® (HDC) inaktiviert auf Verorab® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension Tollwut-Impfstoff, inaktiviert, ...
Sanofi Pasteur, the vaccines division of Sanofi-aventis, has entered into a marketing and distribution agreement with Emcure Pharmaceuticals (Emcure) in India for its anti-rabies vaccine, Verorab. The ...
Wie wirkt der Inhaltsstoff des Arzneimittels? Das Arzneimittel ist ein Impfstoff und wird zur Vorbeugung gegen Tollwut gegeben. Er enthält inaktivierte Tollwut-Viren. Diese inaktivierten Viren im ...
Pre-exposure prophylaxis clinical trials of a 3-dose regimen of Verorab® followed by a booster dose at 1 year in adults and children achieved an adequate immune response.1 Of those who had a booster ...
READING, U.K.--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of Verorab ® (Sanofi (EPA:SASY) (NASDAQ:SNY) Inactivated Rabies Vaccine) in the UK, an inactivated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results